Neurology® Podcast

1. Early predictors of mortality in parkinsonism and Parkinson’s disease: a population-based study 2. [What’s Trending]: Data from the Largest Natural History Study of Stiff Person Syndrome. In the first segment, Dr. Jeffery Ratliff talks with Dr. David Bäckström about his paper on Early predictors of mortality in parkinsonism and Parkinson’s disease. In the second part of the podcast, Dr. Jeffery Ratliff focuses his interview with Marinos Dalakas on Stiff Person Syndrome. DISCLOSURES:Dr. Jeff Ratliff has received speaker honoraria from Teva and US WorldMeds LLC; is the deputy editor for the Neurology Podcast; has been a consultant for UCB Pharmaceuticals, US WorldMeds LLC, Medscape, and Retrophin Inc; and has served on speakers' bureaus for Teva and US WorldMeds LLC. Dr. David C Bäckström holds patents for chemical compounds that may be developed as treatments for premenstrual dysphoric disorder, but has not received any personal compensation for the patents. Dr. David C Bäckström has received Research Support from Swedish Medical Research Council, grant number (K2013- 62X-15224-10-4) and unrestricted grant for Parkinson's disease research and has received foundation and societies research support from Erling Persson Foundation, Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Kempe Foundation, and Swedish Parkinson’s Disease Association. Dr. Marinos Dalakas serves the CIDP steering committee for Novartis and on DSMB for Baxalta and Octapharma, has received funding or served as a travel speaker honoraria for Merck/Serono, OCTAPHARMA, PFIZER AG. Dr. Marinos Dalakas has served on editorial board including Neurology, editorial board (5 years, not compensated), BMC Neurology (Section Editor, 5 years not compensated), Acta Myologica, editorial board (5 years, not compensated), Acta Neurologica Scandinavica editorial board (5 years, not compensated), and Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated). Dr. Marinos Dalakas consultancies include work with Therapath, Baxter, Octapharma, CSL, Dysimmune Diseases Foundation and he has received research and institutional support from Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor.

1. Devastating neurological injuries in the Syrian War 2. [What’s Trending]: Standards for Neurologic Critical Care Units: A Statement for Healthcare Professionals from The Neurocritical Care Society. In the first segment, Dr. Jason Crowell talks with Dr. Maher Saqqur and Yasmeen El Hajj Abdallah about neurological injuries in the Syrian War. In the second part of the podcast, Dr. Andrew Schomer focuses his interview with Dr. Asma Moheet on Standards for Neurologic Critical Care Units. DISCLOSURES: Drs. Jason Crowell, Maher Saqqur, Asma Moheet, and Andrew Schomer report no disclosures. Yasmeen El Hajj Abdallah reports employment with Shoppers Drugmart Pharmacy as pharmacy student for less than one year.

Dr. Alex Menze focuses his interview with Claudia Angeli on recovery of over-ground walking after chronic motor complete spinal cord injury. 

1. Featured Article Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US 2. [What’s Trending]: Acute flaccid myelitis In the first segment, Dr. Nick Brenton talks with Dr. Kristen Krysko about her paper on therapies for pediatric multiple sclerosis. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Kenneth Tyler on acute flaccid myelitis. DISCLOSURES: Dr. Nick Brenton does not report any disclosures.Dr. Kristen Krysko received fellowship support from he National Multiple Sclerosis Society.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for DNAtrix (DSMB, active), LPath (DSMB)(completed), and PML Consortium (Scientific Advisory Board, completed); is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from Taiga Biotechnologies and the NIH/NIAID, 1R01 NS101208, PI, 2018-2022, Dept. of Veterans Affairs Merit Grant (BX000963, Role: PI, 2017-21), NIH/NINDS, (5R21NS103186, PI, 2017-2019); and serves as Officer (Treasurer) and Member Board of Directors American Neurological Association (ANA)- Uncompensated.

This month’s Delayed Recall highlights episodes on stroke risk, prevention and treatment. Dr. Jim Siegler and Dr. Christian Gerloff begin the show discussing the results of the WAKE-UP stroke trial. This episode first aired on October 2, 2018. The next segment, from September 11, 2018 focuses on acute ischemic stroke, where Dr. Dan Ackerman talks with Dr. Andrei Alexandrov about his paper on dual antiplatelet therapy pretreatment. This interview is followed by a segment that first appeared in the August 21, 2018 show on silent infarct and the risk of infarct recurrence in adults with sickle cell anemia with Dr. Justin Sattin and Dr. Lori Jordan. The episode concludes with another interview on acute ischemic stroke from August 14, 2018 investigating a POINT study on Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA with Dr. Will Rondeau interviewing Dr. Clay Johnston.

1. Featured Article: Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 Update2. What’s Trending: Using artificial intelligence in neurological diagnosisDr. Jeff Ratliff talks with Dr. Anup Patel about his paper on the 2017 epilepsy quality measurement set update. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Eric Oermann on the use of artificial intelligence in diagnosing neurological conditions. DISCLOSURES: Dr. Anup D Patel has been a consultant for Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel’s other activities include Greenwich Biosciences, UCB Pharma, LivaNova, and Supernus. Dr. Patel’s has received research support for commercial entities from Greenwich Biosciences Brain Sentinel Upsher Smith Pharmaceuticals LivaNova, and research support from foundations and societies from Pediatric Epilepsy Research Foundation (PERF) American Academy of Neurology (AAN). Dr. Patel’s non-financial disclosures include serving on a voluntary basis as the vice chair for the AAN Quality Safety Subcommittee and as the chair for the Epilepsy Quality Measure work group.Dr. Andy Southerland has served on editorial boards for Journal Neurology, Section Editor Neurology Podcast Patents Intellectual property unrelated to current work: U.S. Patent Application No. 14/910,890 (iTREAT study) U.S. Provisional Patent Application No. 62/620,096 (BANDIT study). Dr. Southerland's consultancies include National Stroke Association - helped develop website for resources regarding telestroke and teleneurology, Research Support, Commercial Entities. Dr. Southerland's Edwards Lifesciences include perform neurological assessments for the PARTNER clinical trials of transcatheter aortic valve replacement. Dr. Southerland's Research Support, Government Entities include Stroke Hyperglycemia Insulin Network Effort (SHINE) NINDS/NIH U-01 NS 069498, Health Resources Services Administration - Evidence based tele-emergency network grant (RURAL EQUIT-E Project) HRSA G01RH27869, and NHLBI/NINDS - Cardiothoracic Surgical Trials Network (CTSN) - performed neurological assessments in conjunction with the neuroprotection trial of aortic valve replacement. Dr. Southerland's Research Support, Foundations and Societies include American Heart Association-American Stroke Association National Clinical Research Program, Cervical Artery Dissection Expression (CADEX) AHA 3CRP141400001, American Academy of Neurology - Education Research Grant, American Board of Psychiatry and Neurology - Faculty Fellowship Award. Dr. Southerland's legal proceedings include Legal Expert Review - perform expert review, on behalf of the UVA University Physician's Group, pertaining to stroke and vascular neurology questions for both plaintiff and defense cases.Dr. Eric Karl Oermann has received research support for foundations and societies from Doris Duke Charitable Research Foundation.

1. Featured Article: “‘Is there a neurologist on this flight?’ An update”2. What’s Trending: paraneoplastic neuronal intermediate filament autoimmunityDr. Jason Crowell talks with Dr. Joseph Sirven about his NCP paper entitled “‘Is there a neurologist on this flight?’ An update.” In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Andrew McKeon on paraneoplastic neuronal intermediate filament autoimmunity.DISCLOSURES:Dr. McKeon has patent applications pending: Septin 5 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; his Consultancies include Grifols Medimmune Euroimmun with no personal compensation received for these activities; he has received research support from Medimmune, Inc Euroimmun Grifols. Dr. Sirven has served on scientific advisory boards Commercial- Advisory role for Eisai, Upsher - Smith Non- profit- Epilepsy Foundation, AAN, FAA; has has funding for travel or speaker honoraria for Epilepsy Foundation- travel; has served on Editorial Boards for Epilepsy.com; has published royalties for Up to Date 2010 Clinical Neurology of the Older Adult, LWW, 2008; has completed projects for Medscape; is on the Board of Directors of the American Brain Foundation; has supported research for Government Entities, NINDS sub Investigator and supported research for Foundations and Societies, Epilepsy Foundation. Dr. McKeon has patent applications pending: Septin 5 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; his Consultancies include Grifols Medimmune Euroimmun with no personal compensation received for these activities; he has received research support from Medimmune, Inc Euroimmun Grifols.

1. Featured Article: Primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome: A comparative study2. What’s Trending: Cannabis and chronic neuropathic painDr. Andy Southerland talks with Dr. Anne Ducros about her paper on primary angiitis of the CNS and reversible cerebral vasoconstriction syndrome. In the second part of the podcast, Dr. Heather Harle focuses her interview with Dr. Haggai Sharon on the use of cannabis analgesia in chronic neuropathic pain. DISCLOSURES:Dr. Ducros has served on scientific Advisory Boards for Novartis, Eli Lilly, and TEVA;has served on editorial boards for Cephalalgia: Associate Editor, Headache: editorial advisory board member, Journal of Headache and Pain: editorial advisory board member. Dr. Sharon reports no disclosures Dr. Southerland has served on editorial boards for Journal Neurology, Section Editor Neurology PodcastPatents Intellectual property unrelated to current work: U.S. Patent Application No. 14/910,890 (iTREAT study) U.S. Provisional Patent Application No. 62/620,096 (BANDIT study). Dr. Southerland's consultancies include National Stroke Association - helped develop website for resources regarding telestroke and teleneurology, Research Support, Commercial Entities. Dr. Southerland's Edwards Lifesciences include perform neurological assessments for the PARTNER clinical trials of transcatheter aortic valve replacement. Dr. Southerland's Research Support, Government Entities include Stroke Hyperglycemia Insulin Network Effort (SHINE) NINDS/NIH U-01 NS 069498, Health Resources Services Administration - Evidence based tele-emergency network grant (RURAL EQUIT-E Project) HRSA G01RH27869, and NHLBI/NINDS - Cardiothoracic Surgical Trials Network (CTSN) - performed neurological assessments in conjunction with the neuroprotection trial of aortic valve replacement. Dr. Southerland's Research Support, Foundations and Societies include American Heart Association-American Stroke Association National Clinical Research Program, Cervical Artery Dissection Expression (CADEX) AHA 3CRP141400001, American Academy of Neurology - Education Research Grant, American Board of Psychiatry and Neurology - Faculty Fellowship Award. Dr. Southerland's legal proceedings include Legal Expert Review - perform expert review, on behalf of the UVA University Physician's Group, pertaining to stroke and vascular neurology questions for both plaintiff and defense cases.

1. Featured Article: Neurology: Clinical Practice: Presentation and management of community onset vs. hospital onset first seizures2. What’s Trending: Acute viral encephalitisIn the first segment, Dr. Katherine Zarroli talks with Dr. Emma Foster about her paper comparing the presentation and management of patients with community- and hospital-onset first seizures attending the same hospital. In the second part of the podcast, Dr. Stacey Clardy and Dr. Kenneth Tyler review the diagnosis and treatment of acute viral encephalitis.DISCLOSURES: Dr. Zarroli reports no disclosures. Dr. Foster has received research support from National Health and Medical Research Council (NHMRC) Medical / Dental Research Postgraduate Scholarship, APP1150482, CIA, funding 2018-2020 and Royal Australasian College of Physicians (RACP) Research entry scholarship, 2018. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for DNAtrix (DSMB, active), LPath (DSMB)(completed), and PML Consortium (Scientific Advisory Board, completed); is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from Taiga Biotechnologies and the NIH/NIAID, 1R01 NS101208, PI, 2018-2022, Dept. of Veterans Affairs Merit Grant (BX000963, Role: PI, 2017-21), NIH/NINDS, (5R21NS103186, PI, 2017-2019); and serves as Officer (Treasurer) and Member Board of Directors American Neurological Association (ANA)- Uncompensated.

This month’s Delayed Recall episode includes interviews on drug pricing. The episode starts with Dr. Jason Crowell’s interview with Dr. Gordon Smith from September 26, 2017 on orphan drug pricing. Following this clip, we have the full-length interview from the December 5, 2017 episode where Dr. Ted Burns speaks with Dr. John Mytinger on the drug Achtar for infantile ataxia. Next, in an interview from the July 4, 2017 podcast, Dr. Stacey Clardy focuses her interview with Dr. Dennis Bourdette on new immunotherapies. In the fourth and final interview, Dr. Ted Burns and reporter Ike Swetlitz discuss drug pricing practices and the different players in determining drug prices, which first aired in the May 1, 2018 episode of the podcast.